Twist Bioscience (TWST) Corporate presentation summary

Strategic platform and technology overview

• B-Body® bispecific antibody platform enables high-throughput discovery and manufacturing with plug-and-play compatibility and robust yields, using nearly 100% human sequences and standard processes.

• Platform supports rapid, iterative design-build-test-learn cycles, accelerating antibody discovery from in silico design to characterized antibody in as little as 2-4 weeks.

• B-Body® antibodies offer high purity, homogeneity, and long-term stability, with purification strategies compatible with standard manufacturing.

Market opportunity and business model

• Addressable market for DNA synthesis and protein solutions exceeds $4B, with blended market growth rate of ~10% and significant upside from new product introductions.

• Proprietary technology expands serviceable available market, targeting therapeutics, diagnostics, and industrial applications.

• AI-enabled discovery and partnerships with large pharma and tech companies drive growth.

Financial details and growth outlook

• Co-exclusive license for B-Body® platform valued at ~$20M, including $13.8M equity investment, $5M cash, and $15M stock.

• All revenue from bispecific antibody discovery and B-Body® licenses flows to the licensee, with Invenra receiving a 20% royalty on licenses sold.

• Transaction is accretive to revenue and adjusted EBITDA in FY27 and beyond; adjusted EBITDA breakeven targeted for Q4 FY2026.